GSK/Tesaro PARP in­hibitor Ze­ju­la wins an­oth­er speedy re­view

Months af­ter part­ner Zai Lab $ZLAB scored an ac­cel­er­at­ed re­view for PARP ther­a­py Ze­ju­la in Chi­na, GSK has se­cured pri­or­i­ty US re­view for the drug, known chem­i­cal­ly as ni­ra­parib, to ex­pand the use of the drug in pa­tients with ad­vanced ovar­i­an can­cer.

GSK $GSK, which shelled out just over $5 bil­lion to swal­low Ze­ju­la-de­vel­op­er Tesaro, said the FDA is ex­pect­ed to make its de­ci­sion by Oc­to­ber 24.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.